Journal article icon

Journal article

Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.

Abstract:

The murine monoclonal antibody OKT3 is the best known of the anti-CD3 antibodies used for the prevention and treatment of renal allograft rejection. Use of this antibody is associated with improved graft outcome but it has a number of adverse effects thought to result from the massive release of pro-inflammatory cytokines. It has been postulated that OKT3 causes cytokine release because of cross-linking of CD3 molecules on the cell surface by bivalent anti-CD3 antibodies, such as OKT3, and th...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Pathology Dunn School
Chatenoud, L More by this author
Koffman, CG More by this author
Expand authors...
Journal:
Therapeutic immunology
Volume:
1
Issue:
6
Pages:
325-331
Publication date:
1994-12-05
ISSN:
0967-0149
URN:
uuid:11bdd514-56b6-4a39-96c0-48f4eaa14912
Source identifiers:
27817
Local pid:
pubs:27817

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP